The creation of an apoB39-only mouse model elucidates the mechanisms by which truncated apoB mutations cause familial hypobetalipoproteinemia and lower plasma cholesterol.
Provides mechanistic insight into familial hypobetalipoproteinemia; leaves open therapeutic translation in humans.
Familial hypobetalipoproteinemia, a syndrome characterized by abnormally low plasma levels of low density lipoprotein cholesterol, is caused by mutations in the apolipoprotein (apo) B gene that interfere with the synthesis of a full-length apoB100. In many cases of familial hypobetalipoproteinemia, nonsense or frameshift mutations result in the synthesis of a truncated apoB protein. To understand why these mutations result in low plasma cholesterol levels, we used gene targeting in mouse embryonic stem cells to introduce a nonsense mutation (N1785Stop) into exon 26 of the mouse Apob gene. The sole product of this mutant Apob allele was a truncated apoB, apoB39. Mice homozygous for this "apoB39-only" (Apob39) allele had low plasma levels of apoB39 and markedly reduced plasma levels of very low density lipoprotein and low density lipoprotein cholesterol when fed a high fat diet. Analysis of liver and intestinal RNA from heterozygous apoB39-only mice revealed that the Apob39 mRNA levels were 60-70% lower than those from the wild-type allele. Interestingly, apoB39 was not cleared as rapidly from the plasma as apoB48. The apoB39-only mice provide new insights into the mechanisms of familial hypobetalipoproteinemia and the structural features of apoB that are important for lipoprotein metabolism.
No takes yet. Share an insight, caveat, or question.
Kim et al. (1998) studied Familial hypobetalipoproteinemia. Apob39 allele (nonsense mutation N1785Stop) vs. Wild-type allele was evaluated on Plasma levels of apoB39, VLDL, and LDL cholesterol; Apob39 mRNA levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: